Adaptive Biotechnologies (ADPT) Net Cash Flow (2018 - 2026)

Adaptive Biotechnologies has reported Net Cash Flow for 9 years, with the latest figure at $7.1 million in Q1 2026.

• Quarterly Net Cash Flow rose 179.76% year-over-year to $7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.9 million (up 229.24% YoY) and the FY2025 annual result came in at $22.4 million, up 230.2% from the prior year.
• Net Cash Flow retreated to $7.1 million in Q1 2026 per ADPT's latest filing, from $15.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $141.1 million in Q3 2022 and troughed at -$127.6 million in Q4 2022.
• A 5-year average of -$3.6 million and a median of $2.5 million in 2025 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 328.42% in 2022, down 865.46% in 2022.
• Over 5 years, Net Cash Flow stood at -$127.6 million in 2022, then surged by 81.47% to -$23.6 million in 2023, then jumped by 141.27% to $9.8 million in 2024, then soared by 58.49% to $15.5 million in 2025, then sank by 54.04% to $7.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered $7.1 million, $15.5 million, and $11.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.